A nine-amino-acid hormone synthesised in the hypothalamus and released from the posterior pituitary. Peripherally it drives uterine contraction and milk ejection through OXTR-mediated calcium signalling. Centrally it modulates social recognition, pair bonding and stress responses — the basis of an enormous and frequently overstated literature. It differs from vasopressin by just two amino acids, and cross-reacts with vasopressin receptors, which is the source of several of its clinical hazards.
The obstetric use is beyond dispute and decades old. The psychiatric literature — intranasal oxytocin for autism, social anxiety, PTSD — is a cautionary tale: early small studies were striking, larger and better-controlled trials have been largely negative, and whether meaningful quantities of intranasal oxytocin even reach the brain remains genuinely unsettled.
FDA-approved (injection) for labour induction and control of postpartum bleeding. Prescription-only. Intranasal formulations for social or psychiatric use are not approved and are compounded or sold illicitly.
The approved use carries a boxed warning against elective induction. Real hazards: uterine hyperstimulation and rupture, and — through vasopressin receptor cross-reactivity — water intoxication with hyponatraemia, seizures and death. This is not a benign “love hormone”; it is a potent obstetric drug.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.